ATTR-ACT LONG-TERM EXTENSION STUDY POINTS TO BETTER SURVIVAL OUTCOMES WITH TAFAMIDIS
The recent ATTR-ACT long-term extension (LTE) study concluded that patients initially treated with tafamidis had significantly better survival than those initially treated with placebo, highlighting the significance of early diagnosis and treatment in transthyretin amyloid cardiomyopathy (ATTR-CM).
Markings
Shape
Form
Color 1
Color 2
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in